456 reports of this reaction
1.5% of all MAGNESIUM SULFATE HEPTAHYDRATE reports
#15 most reported adverse reaction
MACULAR DEGENERATION is the #15 most commonly reported adverse reaction for MAGNESIUM SULFATE HEPTAHYDRATE, manufactured by Baxter Healthcare Corporation. There are 456 FDA adverse event reports linking MAGNESIUM SULFATE HEPTAHYDRATE to MACULAR DEGENERATION. This represents approximately 1.5% of all 30,255 adverse event reports for this drug.
Patients taking MAGNESIUM SULFATE HEPTAHYDRATE who experience macular degeneration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MACULAR DEGENERATION is a less commonly reported adverse event for MAGNESIUM SULFATE HEPTAHYDRATE, but still significant enough to appear in the safety profile.
In addition to macular degeneration, the following adverse reactions have been reported for MAGNESIUM SULFATE HEPTAHYDRATE:
The following drugs have also been linked to macular degeneration in FDA adverse event reports:
MACULAR DEGENERATION has been reported as an adverse event in 456 FDA reports for MAGNESIUM SULFATE HEPTAHYDRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MACULAR DEGENERATION accounts for approximately 1.5% of all adverse event reports for MAGNESIUM SULFATE HEPTAHYDRATE, making it a notable side effect.
If you experience macular degeneration while taking MAGNESIUM SULFATE HEPTAHYDRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.